AAAAAA
Results: 51-62/62
Authors:
HUH K
WILTON JH
NIX DE
SCHENTAG JJ
Citation: K. Huh et al., STRUCTURES AND BIOLOGICAL-ACTIVITIES OF TOBRAMYCIN-TICARCILLIN ADDUCTS, Journal of pharmaceutical sciences, 83(6), 1994, pp. 763-767
Authors:
NIX DE
SYMONDS WT
WILTON JH
REIDENBERG P
TEAL MA
OCONNOR G
SCHENTAG JJ
Citation: De. Nix et al., COMPARATIVE PHARMACOKINETICS OF ORAL CEFTIBUTEN, CEFIXIME, CEFACLOR, AND CEFUROXIME AXETIL IN NORMAL ADULTS, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 192-192
PLASMA-CLEARANCE (CL) OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL-1RA) IN PATIENTS WITH SEPSIS SYNDROME
Authors:
BLOEDOW DC
PRIBBLE JP
CATALANO MA
FISHER CJ
SCHENTAG JJ
JARESKO GS
BARRIERE SL
Citation: Dc. Bloedow et al., PLASMA-CLEARANCE (CL) OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL-1RA) IN PATIENTS WITH SEPSIS SYNDROME, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 196-196
Authors:
DANIELS S
SCHENTAG JJ
Citation: S. Daniels et Jj. Schentag, DRUG-INTERACTION STUDIES AND SAFETY OF FAMCICLOVIR IN HEALTHY-VOLUNTEERS - A REVIEW, Antiviral chemistry & chemotherapy, 4, 1993, pp. 57-64
Authors:
BENET LZ
CHENG YC
COEN DM
CRUMPACKER CS
FIELD HJ
KERN ER
OXFORD J
SACKS SL
SAFRIN S
SCHENTAG JJ
SCHINAZI RF
Citation: Lz. Benet et al., FAMCICLOVIR-PENCICLOVIR - PHARMACOLOGY AND PHARMACOKINETICS WORKSHOP - PROCEEDINGS OF A MEETING HELD AT CLIVEDEN, MAIDENHEAD, UK, ON 23 APRIL 1993 - DISCUSSION AND CONCLUSIONS, Antiviral chemistry & chemotherapy, 4, 1993, pp. 67-68
Authors:
ALIOTH C
BLUM RA
DANDREA DT
KOCHAK GM
TENG LC
ZIEHMER BA
SCHENTAG JJ
CHAN KKH
Citation: C. Alioth et al., APPLICATION OF DUAL RADIOTELEMETRIC TECHNIQUE IN STUDYING DRUG-DRUG INTERACTION BETWEEN DICLOFENAC SODIUM AND RANITIDINE HCL IN VOLUNTEERS, Pharmaceutical research, 10(11), 1993, pp. 1688-1692
Authors:
BIRMINGHAM MC
NIX DE
CUMBO TJ
COLLINS DA
WELS PB
SCHENTAG JJ
Citation: Mc. Birmingham et al., THE DEVELOPMENT OF A BEDSIDE ALGORITHM CAPABLE OF TARGETING ANTI-ENDOTOXINS TO THE RESPONDER SUBPOPULATIONS, Therapeutic drug monitoring, 15(6), 1993, pp. 503-509
Authors:
SCHENTAG JJ
Citation: Jj. Schentag, THE RESULTS OF A TARGETED PHARMACY INTERVENTION PROGRAM, Clinical therapeutics, 15, 1993, pp. 29-36
Authors:
AMSDEN GW
BALLOW CH
SCHENTAG JJ
Citation: Gw. Amsden et al., POPULATION PHARMACOKINETIC METHODS TO OPTIMIZE ANTIBIOTIC EFFECTS, Drug investigation, 5(5), 1993, pp. 256-268
Authors:
FORREST A
BALLOW CH
NIX DE
BIRMINGHAM MC
SCHENTAG JJ
Citation: A. Forrest et al., DEVELOPMENT OF A POPULATION PHARMACOKINETIC MODEL AND OPTIMAL SAMPLING STRATEGIES FOR INTRAVENOUS CIPROFLOXACIN, Antimicrobial agents and chemotherapy, 37(5), 1993, pp. 1065-1072
Authors:
FORREST A
NIX DE
BALLOW CH
GOSS TF
BIRMINGHAM MC
SCHENTAG JJ
Citation: A. Forrest et al., PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS, Antimicrobial agents and chemotherapy, 37(5), 1993, pp. 1073-1081
Authors:
WILSON MF
NIX DE
DANDONA P
SUNG BH
PANYIOTACOPALOUS P
GOLDFARB A
MEHOLICK A
SCHENTAG JJ
IZZO JL
Citation: Mf. Wilson et al., CARDIOVASCULAR, CELLULAR AND MOLECULAR EFFECTS OF ENDOTOXIN IN NORMALMAN, Circulation, 88(4), 1993, pp. 39-39